Assessing Doximity (DOCS) Valuation As Analyst Forecasts Shift Before Key Earnings Release

Doximity (DOCS) is back in focus after its share price reacted to shifting analyst forecasts ahead of the upcoming earnings release, with investors weighing expectations for lower EPS against modest revenue growth.

See our latest analysis for Doximity.

The stock has staged a short term rebound, with a 7 day share price return of 6.51% and a 30 day share price return of 15.69%. However, this sits against a year to date share price return decline of 39.87% and a 1 year total shareholder return decline of 56.14%. This suggests that recent momentum is building after a tougher period, as investors reassess growth prospects and risks ahead of earnings.

If you are looking beyond Doximity in the healthcare technology space, this is a useful moment to scan other opportunities in healthcare focused AI. Check out the 35 healthcare AI stocks

With Doximity trading below some analyst price targets and sentiment reset after weaker billings and softer expectations, is the recent rebound an early entry point, or is the stock already pricing in its future growth?

Advertisement

Most Popular Narrative: 31.1% Undervalued

With Doximity last closing at $26.03 against a narrative fair value of $37.77, the most followed thesis sees a sizeable gap that depends heavily on long term engagement and AI driven tools.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time. This is cited as supporting long-term revenue and margin expansion.

Read the complete narrative.

Want to see what kind of revenue growth path and margin profile that statement assumes? The fair value hinges on a specific mix of steady top line expansion, resilient profitability, and a richer earnings multiple tied to those outcomes.

The narrative applies an 8.25% discount rate to convert those future earnings and cash flows into today’s $37.77 fair value estimate, so understanding how realistic the embedded growth and margin path feels to you is crucial when comparing that figure with the current $26.03 share price.

Result: Fair Value of $37.77 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the thesis also leans on assumptions that could break, including slower revenue visibility and the decision to keep key AI tools free for now.

Find out about the key risks to this Doximity narrative.

Next Steps

With sentiment clearly mixed, this is a good moment to look through the underlying data yourself and decide how compelling Doximity's strengths really are, then weigh those positives using the 4 key rewards

Looking for more investment ideas?

If Doximity has sharpened your thinking, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed themes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:DOCS

Doximity

Operates as a digital platform for medical professionals in the United States.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UG logo
stuart_roberts on Upside Gold ·

An Undervalued 3.3Moz Gold Project in Canada

Fair Value:CA$5.0768.0% undervalued
289 users have followed this narrative
1 users have commented on this narrative
43 users have liked this narrative
GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.3% undervalued
103 users have followed this narrative
2 users have commented on this narrative
29 users have liked this narrative
TO
Tokyo
ABI logo
Tokyo on Anheuser-Busch InBev ·

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

Fair Value:€89.4524.2% undervalued
9 users have followed this narrative
3 users have commented on this narrative
4 users have liked this narrative
OS
oscargarcia
AMZN logo
oscargarcia on Amazon.com ·

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.

Fair Value:US$2803.2% undervalued
66 users have followed this narrative
1 users have commented on this narrative
2 users have liked this narrative

Updated Narratives

KA
kapirey
OGC logo
kapirey on OceanaGold ·

OceanaGold: Potential Upside with High Costs and Mid-Tier Status

Fair Value:CA$65.3336.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18057.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
NWRN logo
HedgeY on Newron Pharmaceuticals ·

Still A Binary Phase III Bet on Evenamide

Fair Value:CHF 1824.4% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.3% undervalued
103 users have followed this narrative
2 users have commented on this narrative
29 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.229.5% undervalued
69 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9326.1% undervalued
1400 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative